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ABSTRACT
MMI270B is a matrix metalloproteinase inhibitor
(MMPI) with in vitro and in vivo activity. To exert optimal
target inhibition, MMPI must be given chronically, and
therefore, oral bioavailability is important. We analyzed the
effect of food intake on AUC0–8 h, Cmax, and Tmax. Seventeen
patients were entered into the study. Doses of MMI270B
were 150, 400, and 600 mg. The first day, patients ingested
the drug in a fasted state and were not allowed to eat for 2 h.
The second day, patients ingested the drug 30 min after a
light breakfast. Mean AUC0–8 h was not significantly influ-
enced by food intake. Plasma concentrations were well
above the IC50 of several MMPs at all doses tested. Mean
Cmax was significantly decreased after food intake. Mean
Tmax was significantly delayed after food intake. Food intake
did not result in a significant change in exposure to
MMI270B (AUC0–8 h) but did result in a significant, al-
though not clinically relevant, decrease in peak plasma levels
and time to reach peak plasma levels. No specific guidelines
concerning the ingestion of MMI270B in either a fed or a
fasted state are recommended.
INTRODUCTION
MMPs2 are a class of structurally related enzymes respon-
sible for the degradation of extracellular matrix that constitutes
connective tissue. Activity of MMP is controlled by naturally
occurring inhibitors, but in several disease states, such as cancer,
an imbalance between the activity of MMP and their inhibitors
results in an increased extracellular matrix degradation. In can-
cer, this degradation facilitates local invasive growth and in-
creases the potential for metastasis. Inhibiting MMP seems an
attractive goal in anticancer treatment. Inhibitors of MMP
should not have a direct cytotoxic effect but should control the
metastatic process (1).
MMI270B (previously CGS 27023A) is a novel MMPI
with an IC50 of 33 nM for recombinant human collagenase
(MMP 1), 8 nM for recombinant human Mr 92,000 gelatinase
(MMP 9), and 13 nM for recombinant human stromelysin-1
(MMP 3). Preclinical studies with oral MMI270B in vivo
showed growth-inhibitory effects in breast carcinoma, prostate,
bladder, colon, lung adenocarcinoma, glioblastoma, and ovarian
carcinoma cell lines. MMI270B is rapidly absorbed after oral
administration in rats and dogs. In fasted rats, bioavailability
after a single oral dose is 44%. Thus far, only one clinical study
with oral MMI270B has been presented (2). Data concerning
bioavailability in humans, and the possible influence of food
intake, have not been published previously. In view of the
mechanism of action of MMPIs, prolonged and continuous
administration will result in optimal target inhibition, and there-
fore, oral treatment is preferred. We performed a Phase I and
pharmacological study with oral MMI270B in patients with
miscellaneous solid tumors (2). As part of this study, we ana-
lyzed the influence of food intake on the pharmacokinetics of
MMI270B, comparing AUC0–8 h (area under the plasma con-
centration versus time profile), Cmax (peak plasma level), and
Tmax (time to peak plasma level) at different dose levels of
MMI270B, after ingestion in both a fasted and fed state.
PATIENTS AND METHODS
Eligibility Criteria. Patients with a cytologically or his-
tologically confirmed diagnosis of a solid tumor refractory to
standard treatment or for which no standard treatment was
available were eligible for the Phase I and pharmacological
study. Further eligibility criteria included: age $21 years, WHO
performance state #2, life expectancy of $12 weeks, no anti-
cancer treatment in the previous 4 weeks (6 weeks for mitomy-
cin C or nitrosoureas), no radiotherapy in the previous 2 weeks,
adequate function of bone marrow [WBC $4.109/l, platelets
$100.109/liter, hemoglobin $9 g/dl (5.59 mmol/l)], normal
hepatic and renal functions (alanine aminotransferase within
three times the normal upper limit, bilirubin within 1.25 times
the normal upper limit, and creatinine within 1.25 times the
normal upper limit). Exclusion criteria were pregnant women,
the evidence of cerebral metastases, or a clinically significant
abnormal electrocardiogram at baseline.
All patients gave written informed consent for the Phase I
and pharmacological study. Patients enrolled in the fasted/fed
study gave additional and specific written informed consent.
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Pretreatment Assessment and Follow-Up Studies.
Prior to therapy, a complete medical history was taken, and a
physical examination was performed. A complete blood count,
including WBC differential, and serum chemistries including
sodium, potassium, calcium, phosphorus, creatinine, total
protein, albumin, glucose, alkaline phosphatase, bilirubin, as-
partate aminotransferase, alanine aminotransferase, g-glutamyl
transpeptidase, and lactate dehydrogenase were performed, as
were urine analysis, electrocardiogram, and tumor markers, if
appropriate. Patients enrolled in the fasted/fed study were ad-
mitted to the hospital for 2 consecutive days for pharmacoki-
netic sampling.
Drug Administration. MMI270B was supplied by No-
vartis Pharma AG (Basel, Switzerland), as a chiral hydroxamic
acid derived from D-valine. It was supplied in capsules of 25,
100, or 300 mg. Capsules had to be stored at temperatures
,25°C and protected from light and had to be swallowed with
250 ml of water. Prophylactic antiemetics were not given rou-
tinely. For pharmacokinetic purposes, capsules were swallowed
once daily on days 1 and 2. For the fasted/fed analysis, capsules
were swallowed in a fasted state on day 1, and patients were not
allowed to eat or drink for 2 h after ingestion. On the second day
of treatment, patients swallowed the capsules 30 min after they
had eaten a light breakfast.
Pharmacokinetic Studies. Five-ml blood samples were
taken from an i.v. cannula that was inserted in the forearm. On
day 1, blood samples were taken predose and 30, 60, and 90 min
and 2, 3, 4, 6, 8, 12, and 24 h postdose, prior to the morning
dose. On day 2, blood samples were taken predose, 30, 60, and
90 min and 2, 3, 4, 6, and 8 h postdose. Blood samples were
collected in heparin-containing Vacutainer tubes that were
gently inverted 8–10 times. Within 30 min after collection,
samples were centrifuged at 2500 rpm at room temperature for
15 min, after which plasma was transferred into plastic tubes
with a pipette and stored at 220°C until analysis. Determination
of plasma concentrations of MMI270B was performed using a
validated high-performance liquid chromatography method.
MMI270B and the internal standard (CGS 26835) were ex-
tracted from acidified human plasma by ether:methylene chlo-
ride (2:1). The organic layer was transferred and evaporated to
dryness under nitrogen, and the residue was reconstituted in
high-performance liquid chromatography mobile phase for sam-
ple injection. Chromatographic separation of the compounds
was achieved on a 5-mm Zorbax SB-C18 analytical column (4.6
mm inside diameter 3 150 mm), using acetic acid (pH 3.00):
acetonitrile with 9% methanol (80:20, v/v) as the mobile phase
at a flow rate of 1 ml/min. The effluent from the column was
monitored by UV detection at 242 nm. The lower limit of
quantitation was 20 ng/ml, and the method had a linear range
over the concentration range of 20 to 2000 ng/ml. The noncom-
partmental pharmacokinetic parameters AUC0–8 h, Cmax, and
Tmax data were calculated using WinNonlin Professional version
1.5 software (Scientific Consulting, Inc.). For AUC0–8 h and
Cmax, the fed:fasted ratio was determined; for Tmax, the time
difference fed-fasted was determined.
Statistical Considerations. The correlation between in-
dividual AUC0–8 h values and the administered dose was eval-
uated by means of Spearman’s correlation coefficient (r) and
linear regression analysis. Interpatient differences in pharmaco-
kinetic parameters were assessed by the coefficient of variation,
expressed as the ratio of the SD and the observed mean. Vari-
ability in parameters between the two treatment courses and the
various MMI270B dose levels was evaluated by a two-sided
paired Student’s t test plus the 95% confidence limits for the
mean difference (d) and the Kruskal-Wallis statistic, respec-
Table 1 Summary of MMI270B Pharmacokinetic Data after oral administrationa
Dose (mg) Fed Fasted 95% CLb Pc
AUC (ngzh/ml) 150 799.3 6 501.9 967.0 6 556.8 2282,d,254.0 0.018
400 2422 6 1246 2406 6 1127 2319,d,351 0.901
600 6787 6 3151 7711 6 3592 22859,d,1009 0.297
Cmax (ng/ml) 150 485.0 6 340.6 1091 6 536.4 21080,d,2131 0.027
400 1754 6 969.8 2838 6 2015 23041,d,872 0.199
600 4406 6 2264 7432 6 5158 26401,d,349 0.072
Tmax (h) 150 1.14 6 0.78 0.53 6 0.04 20.58,d,1.81 0.201
400 1.18 6 0.46 0.50 6 0.01 0.11,d,1.26 0.030
600 0.91 6 0.35 0.92 6 0.42 20.17,d,0.41 0.975
a Data were obtained from 17 cancer patients treated on day 1 with MM1270B at dose levels of 150 mg (n 5 4), 400 mg (n 5 5), or 600 mg
(n 5 8) after an overnight fast (Fasted) and on day 2 at 30 min after a light breakfast (Fed). Data were calculated by noncompartmental analysis and
represent mean values 6 SD.
b 95% CL, 95% confidence limits for the mean difference.
c Probability value from a two-sided paired Student’s t test.
Fig. 1 Concentration versus time profile of MMI270B in a represent-
ative patient (dose, 600 mg).
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tively. Statistical calculations were performed using Number
Cruncher Statistical System (version 5.X; Jerry Hintze, East
Kaysville, UT). Probability values of ,0.05 were regarded as
statistically significant.
The 90% confidence intervals for the ratio of means fed
versus fasted for the parameters AUC0–8 h and Cmax were cal-
culated using the ANOVA program of WinNonlin Professional
version 1.5 (Scientific Consulting, Inc.).
RESULTS
Seventeen patients were entered into the study. In one
patient, blood sampling on day 2 was done until 6 h postdose.
Doses studied were 150, 400, and 600 mg. None of the patients
used prokinetic medication, antacids, or other concomitant med-
ication expected to alter gastrointestinal motility.
Pharmacokinetic Results. Mean drug exposure
(AUC0–8 h) was related to dose (fed: Spearman’s r5 0.876 and
P 5 0.0007; fasted: Spearman’s r5 0.869 and P 5 0.0008),
whereas the influence of food intake on drug exposure was
diverse; in 12 patients, food intake resulted in a decreased drug
exposure, whereas in 4 patients, an opposite effect was noted
(Fig. 1; Table 1). In one patient, food intake had no effect on
drug exposure. Overall, mean exposure to MMI270B was re-
duced by 10% after food intake. The 90% confidence interval
for the ratio of means fed versus fasted (0.816–0.986) lies
within the range 0.8–1.25, indicating no significant effect of
food intake on AUC0–8 h. Both in the fed and fasted states and
at all doses analyzed, plasma levels of MMI270B were well
above the IC50 for the target enzymes collagenase-MMP 1,
gelatinase-MMP 9, and stromelysin-MMP 3 for considerable
periods of time after administration.
Mean peak plasma levels were strongly correlated to dose
(fed: Spearman’s r5 0.850 and P 5 0.0013; fasted: Spearman’s
r5 0.691 and P 5 0.0116). In three patients, peak plasma levels
in the fed state were higher than in the fasted, whereas in 14
patients, peak plasma levels decreased after food intake. Mean
Cmax was 40% lower in the fed state. The 90% confidence
interval for the ratio of means fed versus fasted (0.457–0.778)
almost entirely falls outside the range (0.7–1.43), indicating a
significant effect of food intake on Cmax.
Mean time to reach peak plasma levels (1.04 6 0.488 h fed
state, 0.704 6 0.388 h fasted state) was significantly increased
by food intake (P 5 0.042; 95% confidence limits for the mean
difference: 0.04,d,0.65). The absolute increase in mean time
to reach peak plasma levels was 0.34 h (or 20 min).
DISCUSSION
We have performed a pharmacological study with the oral
MMPI MMI270B to analyze the influence of food intake on the
pharmacokinetic parameters AUC0–8 h, Cmax, and Tmax.
The results of this study show that exposure to MMI270B
was not significantly influenced by food intake, and plasma
levels of MMI270B in both the fasted and fed state, at all dose
levels studied, remained well above the IC50 of the MMP 1,
MMP 3, and MMP 9 for prolonged periods of time. Peak plasma
levels of MMI270B were significantly influenced by food in-
take, and a correlation between change in overall drug exposure
and change in peak plasma level could be determined. Although
food intake significantly slowed the rate of absorption of
MMI270B, the absolute change in Tmax is not clinically rele-
vant, especially when taking into account that MMPIs have to be
administered on a continuous and prolonged basis to exert
optimal target inhibition.
The results of this pharmacokinetic study indicate that
although food intake slows the rate of absorption of MMI270B
and significantly decreases peak plasma levels, overall drug
exposure is not significantly influenced. No specific guidelines
concerning the ingestion of MMI270B in either a fed or a fasted
state are recommended.
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